- Tryp announced its inclusion in the AdvisorShares Psychedelics ETF
- The company hopes that its participation will open it up to a more diverse shareholder base and broaden its life science exposure
- Tryp’s presentation at the KCSA Virtual Investor Conference will also be available for on-demand viewing over the next 90 days
Launched back in September 2021, the AdvisorShares Psychedelics Exchange-Traded Fund (“ETF”) has been actively trading, focusing on enterprises that have devoted a significant proportion of their assets to psychedelic drug development. Operating under the ticker symbol “PSIL” on the New York Stock Exchange (“NYSE”) Arca exchange, this fund has built a portfolio that includes over 25 different psychedelic companies. Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is the latest addition to that group.
Tryp is excited with its inclusion in the fund, particularly since it provides an opportunity to bring a more diverse shareholder base while also broadening life science exposure for the company (https://ibn.fm/8DMHm). Its operations and commitment to developing psilocybin-based compounds for ailments with high unmet medical needs line up with AdvisorShares ETF’s main objective and focus.
Interested parties can now also access Tryp’s KCSA Psychedelics Virtual Investor Conference presentation. In partnership with KCSA Strategic Communications, Virtual Investor Conferences announced that this and other presentations from critical players within the psychedelics space are now available for on-demand viewing (https://ibn.fm/oVNWI).
The two-day event, held on October 13-14, 2021, featured a live overview of Tryp’s activities while elaborating on how it is leading the next wave of psychedelic drug development beyond mental health, focusing on chronic pain and other indications (https://ibn.fm/DcNgu).
These presentations will be available 24/7 over the next 90 days. Interested parties, analysts, investors, and advisors can also download shareholder materials from the company’s “virtual trade booth.”
For those who wish to access the presentations, you can register or log in now at https://ibn.fm/ZQiNc
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
